Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma
- 21 February 2018
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 93, 57-68
- https://doi.org/10.1016/j.ejca.2018.01.073
Abstract
No abstract availableKeywords
Funding Information
- III
- CNS
- CNS
- CNS
- Roche
- UM
- JC
- Celgene
- Roche
- Celgene
- Gilead
- Roche
- Novartis
- Celgene
- Gilead
- A.P. Møller og hustru Chastine Mc-Kinney Møllers Fond til almene formal (TCEG)
- UF
This publication has 42 references indexed in Scilit:
- Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)Journal of Clinical Oncology, 2013
- Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomasPublished by Ferrata Storti Foundation (Haematologica) ,2012
- Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation - an International Primary Central Nervous System Lymphoma Study Group projectHaematologica, 2012
- Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapsePublished by Ferrata Storti Foundation (Haematologica) ,2011
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab EraJournal of Clinical Oncology, 2010
- Testicular lymphoma, intraocular (Vitreoretinal) lymphoma, and brain lymphoma: Involvement of three immunoprivileged sites in one patientAmerican Journal of Hematology, 2010
- Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapyAnnals Of Oncology, 2009
- CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)Blood, 2009
- Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516—The Southwest Oncology GroupJournal of Clinical Oncology, 2009
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993